Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
Arturo Cesaro, Assistant Professor of Cardiology at University of Campania “Luigi Vanvitelli”, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Just published in European Journal of Preventive Cardiology
Proud to share our newly published systematic review and meta-analysis evaluating the impact of semaglutide on peripheral artery disease (PAD)-related outcomes.
First meta-analysis focusing on PAD as a hard endpoint across randomized trials
Key takeaways
- Semaglutide was associated with a significant reduction in limb events
- Findings support a potential vascular protective role beyond coronary disease, extending to the peripheral circulation
A step forward in extending cardiometabolic prevention beyond the coronary circulation.
Huge thanks to all co-authors and collaborators for an outstandingy team effort.”
Title: Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Authors: Arturo Cesaro, Vincenzo Acerbo, Miriam Longo, Alessandra Antonucci, Maria Ida Maiorino, Maria Grazia Monaco, Eugenio Martelli, Giorgio Giudice, Katherine Esposito, Francesco Giorgino, Massimo Federici, Paolo Calabrò
Read the Full Article on European Journal of Preventive Cardiology
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 16, 2026, 17:42Mohamed Sherif Salem: Turning 2026 KDIGO Complexity into Bedside Clarity
-
Mar 16, 2026, 17:39Julie Cardoso: What Happens to Venous Valves When a Blood Clot Forms?
-
Mar 16, 2026, 17:38Nasir Jamal: Blood Transfusion Criteria and Hemodialysis Thresholds in ESRD Patients
-
Mar 16, 2026, 17:37Octavio Cosín Sales: Understanding the Influence of Systemic Factors on Chronic Venous Insufficiency
-
Mar 16, 2026, 17:35Shiny K. Kajal: From Simple Calcium Chelation to Full-Blown Red Cell Metabolic Engineering
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes